Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
US clinical stage biotech AnaptysBio suffered another disappointment with its anti-interleukin-33 (IL-33) monoclonal antibody etokimab, when it yesterday reported top-line data from a week 8 interim analysis of the company’s ongoing ECLIPSE Phase II clinical trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). 11 August 2020
Biotechnology
Novartis has submitted a dossier to the Russian Ministry of Health for registration of its gene therapy Zolgensma (onasemnogene abeparvovec-xioi), which is intended for the treatment of spinal muscular atrophy (SMA). 11 August 2020
Biotechnology
Investors initially reacted positively to Verastem's proposed licensing deal for Copiktra (duvelisib), sending the US biotech firm’s shares up 6.4% to $1.58, but soon lost interest, leaving the stock hardly changed by late morning. 10 August 2020
Biotechnology
Ligandal, a genetic medicine company that uses nanotechnology to develop targeted and personalized therapies, has announced the positive results of laboratory studies that demonstrate the effectiveness of its synthetic peptide, SARS-BLOCK, as a combination treatment and vaccine to COVID-19. 10 August 2020
Biotechnology
Bristol Myers Squibb has licensed its fourth TriNKET immunotherapy drug candidate under its agreement with Cambridge, USA-based Dragonfly Therapeutics. 10 August 2020
Biotechnology
Shares of clinical-stage US biotech Immunic were up nearly 7% at $20.15 in morning trading, after it announced the closing of an underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares. 10 August 2020
Biotechnology
US clinical-stage biotech Pieris Pharmaceuticals saw its shares gain more than 18% to $3.19 in pre-market trading today, after it announced a clinical trial collaboration and supply agreement US pharma major Eli Lilly. 10 August 2020
Biotechnology
Swiss pharma giant Roche announced top-line results from its Phase III program evaluating etrolizumab in moderately to severely active ulcerative colitis (UC). 10 August 2020
Biotechnology
Shares of US biotech major Biogen rose 12% to $310 in early trading on Friday, after the company announced that the US Food and Drug Administration has accepted for priority review the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease. 10 August 2020
Biotechnology
The European Investment Bank (EIB) and EryDel SpA have signed a contract to provide a loan of 30 million euros ($35.4 million) to the Italian biotech company EryDel. 10 August 2020
Biotechnology
US biotech Novavax saw its shares gain as much as 6% on Friday, after it revealed it has entered into a partnership with Japan’s largest drugmaker Takeda Pharmaceutical for the development, manufacturing and commercialization of NVX CoV2373, Novavax’ COVID 19 vaccine candidate, in Japan. 8 August 2020
Biotechnology
The US Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. This is the first oral drug approved to treat this disease. 8 August 2020
Biotechnology
US biotech Denali Therapeutics yesterday signed a binding agreement with Biogen to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease. 7 August 2020
Biotechnology
The Phase III IMpassion131 study, evaluating Tecentriq (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-free survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. 7 August 2020
Biotechnology
A license agreement between USA-based Novavax and the Serum Institute of India will provide for wider access to NVX‑CoV2373, the firm’s COVID‑19 vaccine. 7 August 2020
Biotechnology
A new report from the advocacy organization the Alliance for Regenerative Medicine (ARM) paints an encouraging picture for the sector in the pace of the COVID-19 epidemic that is raging around the world, and which has also had a negative impact on many drugmakers as they reported second-quarter financials over the past couple of weeks. 7 August 2020
Biotechnology
Chinese companies ImmVira Group and Shanghai Pharmaceuticals Holding have entered into a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors. 7 August 2020
Biotechnology
In the second quarter of 2020, the acquisition of rival cancer specialist Celgene drove revenues at Bristol-Myers Squibb to $10.1 billion, a rise of 61% on the same period of 2019 and roughly what analysts were expecting. 6 August 2020
Biotechnology
Swiss biotech venture accelerator and incubator BaseLaunch has announced the fifth partner in BaseLaunch Phase II, the next stage in its company building activities. 6 August 2020
Biotechnology
A more upbeat financial results statement from Germany’s Merck KGaA reflects rebounding sales in key markets, with falling COVID-19 rates enabling countries to relax lockdown measures. 6 August 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze